{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-25-000105","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.151474+00:00","generated_at":"2026-05-17T15:40:05.568969+00:00","sec_items":["2.02","2.05","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce","bullets":["Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.","Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.","Withdrew 2025 revenue guidance pending new leadership's business review.","CEO Bernd Brust recently appointed; EVP CCO Rebecca Buzzeo and EVP CAO Pete Leddy departing.","Base business revenue (ex high-volume CleanCap) grew 5% YoY; positive free cash flow expected by H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-25-000105","json":"https://secwatch.observer/filing/0001823239-25-000105.json","markdown":"https://secwatch.observer/filing/0001823239-25-000105.md","text":"https://secwatch.observer/filing/0001823239-25-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000105/0001823239-25-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000105/mrvi-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:40:05.568969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2727f5702adfbfa698e06819c06618461c0d7ead","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. announced a restructuring with charges of $8.0 million to $9.0 million affecting the Company's workforce (approximately 25% of the Company's workforce).","evidence_excerpt":"On August 11, 2025, the Company announced an organizational restructuring, including a workforce reduction, to reduce operating costs. The workforce reduction, which is being implemented as part of a strategic cost-reduction initiative, was committed to by management on August 8, 2025 and is expected to impact approximately 25% of the Company’s workforce. In connection with the workforce reduction, the Company currently estimates it will incur restructuring and related costs in the range of $8.0 million to $9.0 million, consisting primarily of employee severance and benefits costs, the majority of which the Company expects to recognize in the second half of 2025.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000105/0001823239-25-000105-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$8.0 million to $9.0 million"},{"label":"Affected area","value":"the Company's workforce"},{"label":"Headcount","value":"approximately 25% of the Company's workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}